clinical trial · NCT07706166
Letermovir for R+ Study
University of Wisconsin, Madison·phase4·not yet recruiting·n = 146
Kidney TransplantLiver TransplantLetermovir
brief summary
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
started
Aug 1, 2026
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Jul 15, 2026
detailed description
This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.
official title
An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol